Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update

Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented at ERA 2025, ASN kidney week 2025 and at WCN 2026Analysis of data for patients with lower baseline eGFR showed consistent and pronounced treatment effect in Phase 2 program, further supporting the Company’s plans to advance development in stage 3b/4 diabetic kidney disease (DKD) Novel composition